Page 34 - Read Online

Kapaki et al. Neuroimmunol Neuroinflammation 2020;7:319-29 I http://dx.doi.org/10.20517/2347-8659.2019.26 Page 329

31. Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a
biomarker of Alzheimer’s disease. Nat Commun 2020;11:1683.
32. Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, et al. Cerebrospinal fluid TAR DNA-binding protein 43 combined
with tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders. Dement
Geriatr Cogn Disord 2017;44:144-52.
33. Paraskevas GP, Bourbouli M, Zaganas I, Kapaki E. The emerging TDP-43 proteinopathy. Neuroimmunol Neuroinflammation 2018;5:17.
34. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF alpha-synuclein in the differential diagnosis of
dementia with Lewy bodies vs. normal subjects and patients with Alzheimer’s disease. PLoS One 2013;8:e81654.
35. Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, et al. Neuropsychiatric symptoms and α-Synuclein profile
of patients with Parkinson’s disease dementia, dementia with Lewy bodies and Alzheimer’s disease. J Neurol 2018;265:2295-301.
36. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other
biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 2020;26:379-86.
37. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, et al. High-precision plasma β-amyloid 42/40 predicts current and future
brain amyloidosis. Neurology 2019;93:e1647-59.
38. Wallin A, Kapaki E, Boban M, Engelborghs S, Hermann DM, et al. Biochemical markers in vascular cognitive impairment associated
with subcortical small vessel disease - A consensus report. BMC Neurol 2017;17:102.
39. Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, et al. Circulating interleukin-15 in dementia disorders. J Neuropsychiatry
Clin Neurosci 2007;19:318-25.
40. Rentzos M, Zoga M, Paraskevas GP, Kapaki E, Rombos A, et al. IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer’s
disease and frontotemporal dementia. J Geriatr Psychiatry Neurol 2006;19:114-7.
41. Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with
Alzheimer’s disease and frontotemporal dementia. J Neurol Sci 2006;249:110-4.